Research Protocols
Overview
Standardized experimental frameworks for peptide research — study design, compound characterization, dosing and combination templates, data collection, and safety monitoring. These support reproducible research and assume compliance with institutional ethics and animal-care approval; they are not clinical procedures.
Study Design Framework
| Element | Consideration |
|---|---|
| Research question | Specific, measurable, achievable, relevant, time-bound |
| Hypothesis | State null and alternative hypotheses clearly |
| Endpoints | One primary endpoint (powered) + secondary endpoints |
| Sample size | Power analysis (e.g. α = 0.05, power ≥ 0.80) |
| Controls | Vehicle control, positive control (if available), sham |
| Blinding & randomization | Blind assessment; use a randomization schedule |
Compound Characterization
| Test | Requirement | When |
|---|---|---|
| HPLC purity | ≥ 95% (≥ 98% preferred) | Before study start |
| Mass spectrometry | Confirm molecular weight / identity | Per lot |
| Endotoxin (LAL) | Within limit for the route used | Per lot |
| Sterility | Per applicable standard | Per lot |
| Visual inspection | Clear, particulate-free solution | Before each use |
Standard Dosing Protocol Template
- Define compound, concentration, route, dose, frequency and cycle length up front.
- Fix the timing (e.g. same time of day) and the injection sites / rotation.
- Pre-calculate withdrawal volumes for each dose from the stock concentration.
- Record every administration (time, dose, site, lot, aliquot).
Combination Protocol Templates
GHRP + GHRH (e.g. GHRP-2 + CJC-1295)
Pairs a ghrelin-receptor agonist with a GHRH-receptor agonist — different second messengers (Ca²⁺/IP₃ vs cAMP) studied for complementary GH release. Administer as separate injections.
BPC-157 + TB-500
Complementary tissue-repair mechanisms. Reconstitute and store separately; inject at separate sites rather than mixing in one vial.
Semax + Noopept
A cognitive research combination (intranasal + oral). Keep dosing logs separate for each compound.
Data Collection Schedule
- Baseline measurements before the first dose.
- Defined interim time points matched to the compound’s half-life and expected onset.
- Endpoint measurements at cycle end, plus any washout follow-up.
- Where relevant, hormone or biomarker panels (e.g. IGF-1 for GH secretagogues; glucose for metabolic peptides).
Safety Monitoring
- Pre-study: confirm compound characterization and define stopping criteria.
- During study: monitor for adverse events on a defined schedule; grade and record them.
- Follow institutional reporting requirements for any serious adverse event.
Statistical Analysis & Records
- Pre-specify the analysis plan (tests, α level, handling of missing data).
- Keep lot numbers, reconstitution details, storage conditions and freeze-thaw counts with the dataset.
- Retain Certificates of Analysis alongside experimental records for traceability.
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
Need research-grade peptides?
HPLC-verified, COA per batch. Tell us the quantity you need.
